Statistics for Taysha Gene Therapies (id:8424 TSHA)

Valuation metrics

Market cap

411.94M

Enterprise value

441.36M

Trailing P/E (ttm)

3.19

Forward P/E

-4.79

PEG ratio

-4.79

Price/Sales (ttm)

41.55

Price/Book (mrq)

6.05

Enterprise Value/Revenue

44.51

Enterprise Value/EBITDA

-5.44

Overview

Shares outstanding

204.94M

Float

159.80M

Shares short

17.64M

% Held by insiders

0.18%

% Held by institutions

0.77%

Average volume (10 days)

8.08M

Average volume (90 days)

Price summary

52-Week low

1.19

52-Week high

4.32

52-Week change

27.13%

Beta

0.41

50-Day moving average

1.98

200-Day moving average

2.40

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-229.67%

Operating margin

-1,177.85%

Operational effectiveness

Return on assets

-27.42%

Return on equity

-114.77%

Income statement

Revenue (ttm)

0.04

Revenue per share (ttm)

0.04

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-81,154,000.00

Net income to common (ttm)

-22,772,000.00

Diluted EPS (ttm)

0.63

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

157.69M

Total cash per share (mrq)

0.59

Total debt (mrq)

60.72M

Total Debt/Equity (mrq)

68.38

Current ratio (mrq)

550.70%

Book value per share (mrq)

0.33

Cash flow

Cash flow statement

-110,768,000.00

Levered free cash flow (LFCF)

-111,566,000.00